FY ended March 2024
- Overall sales increased 7.4% over the previous fiscal year. In Japan, the Company concentrated on enhancing sales activities which match each market; the acute care hospital market, the small and mid-sized hospital market, and the clinic market. The Company also focused on its consumables and services business as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. As a result of these initiatives, sales in all markets and all product categories increased. Internationally, sales showed double-digit growth due to yen depreciation and the impact of a change in the fiscal term of Defibtech, LLC according to the reorganization of subsidiaries in the U.S.
*Defibtech, LLC changed its fiscal term from end on December 31 to end on March 31, according to the reorganization of U.S. subsidiaries. In FY2023 ended March 31, 2024, Nihon Kohden consolidated the 15 months of Defibtech’s operating results from January 1, 2023 to March 31, 2024. - Operating income decreased 7.2% because of increases in the cost of goods sold due to an increase in devaluation of inventories, as well as increased SG&A expenses due to the strengthening of human resources and R&D investment.
- Ordinary income increased 6.1%, reflecting foreign exchange gains.
- Income attributable to owners of parent decreased 0.5% because of an increase in the tax burden ratio due to an impact of losses before income taxes in some subsidiaries of the Company, while gain on revision of retirement benefit plan was recorded as extraordinary income.
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Net Sales | 185,007 | 199,727 | 205,129 | 206,603 | 221,986 |
| Operating Income | 15,503 | 27,094 | 30,992 | 21,120 | 19,591 |
| Ordinary Income | 14,846 | 28,374 | 34,563 | 24,122 | 25,589 |
| Income Attributable to Owners of Parent | 9,854 | 18,243 | 23,435 | 17,110 | 17,026 |
| Net Income per Share (EPS) (yen) | 115.72 | 214.21 | 276.51 | 203.28 | 202.45 |
| Total Assets *1 | 167,786 | 193,030 | 210,201 | 216,728 | 233,233 |
| Net Assets | 121,774 | 138,986 | 156,381 | 167,604 | 181,082 |
| Equity Ratio(%) | 72.6 | 72.0 | 74.4 | 77.3 | 77.6 |
| Return on Equity (ROE)(%) | 8.3 | 14.0 | 15.9 | 10.6 | 9.8 |
| Return on Assets (ROA)(%) | 8.8 | 15.7 | 17.1 | 11.3 | 11.4 |
|
- Since the beginning of fiscal year ended March 31, 2019, the Company has applied the partial amendments to the Accounting Standard for Tax Effect Accounting (ASBJ No.28, February 16, 2018). These accounting standards apply to the previous fiscal year's figures retrospectively.
- Number of Employees at the end of each fiscal year.
Caution
-
These data are prepared based on the financial results reports.
-
The frequency of updates may change in accordance with changes to the format of the financial results reports.
-
Please see the financial results reports and other materials for detailed information regarding the settlement of accounts.
-
The contents of these data will not immediately reflect corrections to the financial results reports when announced.
-
While we pay due caution to the conversion of data for the posting, please note that there is a possibility that errors may occur in the information due to uncontrollable circumstances, such as the unauthorized alteration of contents by a third party or mechanical defects resulting from equipment malfunction.
-
Service provided by Nomura Investor Relations Co., Ltd.
Powered by ShareWith
